ClinicalTrials.gg
CompletedNCT02121665Updated Jul 27, 2016

Efficacy of a Probiotic Lozenges in Chronic Periodontitis Patients.

A Phase 3 interventional study of Probiotic (Inersan) and Placebo in Chronic Periodontitis, sponsored by CD Pharma India Pvt. Ltd.. Completed at 1 site in India. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-07-27.

Sponsored by CD Pharma India Pvt. Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Chronic Periodontitis with a site in India — 2 open to participants now, 3 under way, none of them phase 3. Chronic Periodontitis · India.

Enrollment
30th of 46
42 · median 53
Started
2014
with 6 others
Phase 3
8 of 53
none open now
Registered
11th of 53
by date
Lead sponsor
3 of 53
CD Pharma India Pvt. Ltd.

Among the 53 studies in Chronic Periodontitis with a site in India, this one is the 30th largest by enrollment of the 46 interventional ones that give a count, is one of 7 that started in 2014, is one of 8 in phase 3, and was the 11th registered.

Chronic Periodontitis

377 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.

Browse Chronic Periodontitis studies →

Open to participants now

2 of the 53 studies in Chronic Periodontitis with a site in India are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 13 Chronic Periodontitis studies recruiting now, 7 (54%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Chronic Periodontitis with a site in India, or all of them as a file.
02

Study summary

Periodontal disease is an infectious disease resulting in inflammation within supporting tissues of the teeth, progressive attachment loss, and bone loss. Epidemiological studies reveal that about 10% of the adult population suffer from severe periodontitis.It comprises of two distinct but interconnected etiologic components: the periodontopathic bacteria adjacent to the periodontal tissues, and the host-mediated connective tissue-destructive responses to the causative bacteria and their metabolic products. In the arena of periodontics, the probiotics pose a great potential of plaque modification, halitosis management, altering anaerobic bacteria colonization, improvement of pocket depth, and clinical attachment gain.

Aim of the study is to analyze the beneficial effect of probiotic lozenges as an adjunct to Scaling and Root Planing, on clinical and biochemical parameters.

03

Conditions studied

  • Chronic Periodontitis

Browse trials for

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject of both sexes
  • Age group of 25-65 years
  • Subjects with generalized moderate to severe chronic periodontitis
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Any known history of systemic diseases
  • Patients already on anti-inflammatory drugs or antibiotics
  • Patients allergic to any material used in the study
  • Pregnant and lactating women
  • Periodontal therapy in past 6 months
  • Current smoker or smoker in the past
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Probiotic (Inersan) Arm

    Inersan Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2

    Drug: Probiotic (Inersan)

  • Placebo comparator
    Placebo Arm

    Placebo Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)

    Drug: Placebo

Interventions

  • Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2

  • DrugPlacebo

    Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)

06

What researchers measure

Primary outcomes

  1. Improvement in Periodontal Clinical indices

    Improvement in periodontal clinical indices, namely, Gingival Index (GI), Plaque Index (PI), Probing Pocket Depth (PPD) and Clinical attachment Loss (CAL).

    Time frame: 6 weeks

Secondary outcomes

  1. Improvement in biochemical indices

    Changes in level of inflammatory markers namely PGE2, IL-1beta, TNF-alpha, receptor activator of nuclear factor kappa B ligand (RANKL), Osteoprotegerin (OPG), MMP-9 and MMP-13 in saliva sample

    Time frame: 6 weeks

07

Study locations

1 site
  • Department of Periodontics, Government Dental College & Hospital
    Aurangabad, Maharashtra 415570, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Jan 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2014
First posted
Apr 23, 2014
Start
Jul 2014
Primary completionActual
Jan 2016
CompletionActual
Mar 2016
Last update
Jul 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02121665
Lead sponsor
CD Pharma India Pvt. Ltd.
Collaborators
Government Dental College and Hospital, India
Responsible party
Sponsor
First posted
Apr 23, 2014
Start date
Jul 2014
Primary completion
Jan 2016
Completion
Mar 2016
Last update
Jul 27, 2016

Study contacts

Rohan Sethi, BDS
principal investigator · Government Dental College & Hospital, Aurangabad

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion